Tiansheng Pharmaceutical Group Co., Ltd. (SHE:002872)
China · Delayed Price · Currency is CNY 6.03
+0.08 (1.34%)
Sep 2, 2026, 3:04 PM CST
SHE:002872 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 514.89 | 514.09 | 569.71 | 579.33 | 606.99 | 736.69 |
Revenue Growth | -1.07% | -9.76% | -1.66% | -4.56% | -17.61% | -38.75% |
Gross Profit Gross Profit Growth | 239.94 | 239.67 | 261.14 | 256.97 | 327.89 | 295.12 |
Operating Income Operating Income Growth | -62.4 | -55.26 | -60.56 | -85.96 | -93.65 | -72.44 |
Net Income Net Income Growth | -42.88 | -55.42 | -87.4 | -93.07 | -90.56 | -67.81 |
Earnings Per Share EPS Growth | -0.13 | -0.17 | -0.27 | -0.29 | -0.28 | -0.21 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Pharmaceutical Manufacturing Pharmaceutical Manufacturing Growth | 455.98 | 515.6 | 523.42 | 573.28 | 445.34 |
Pharmaceutical Distribution Pharmaceutical Distribution Growth | 17.15 | 13.3 | 17.14 | 3.95 | 267.59 |
Unallocated Other Income Unallocated Other Income Growth | 40.96 | 40.81 | 38.78 | 29.76 | 23.75 |
Total Total Growth | 514.09 | 569.71 | 579.33 | 606.99 | 736.69 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 270.73 | 280.47 | 270.42 | 192.71 | 278.25 | 420.68 |
Total Debt Total Debt Growth | 324.72 | 359.4 | 367.61 | 325.58 | 329.17 | 413.78 |
Net Cash (Debt) Net Cash Growth | -53.99 | -78.93 | -97.19 | -132.86 | -50.92 | 6.89 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -0.17 | -0.25 | -0.31 | -0.42 | -0.16 | 0.02 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 61.97 | 42.97 | 50.15 | -24.56 | 89.18 | 18.97 |
Capital Expenditures CapEx Growth | -29.46 | -26.92 | -50.27 | -76.74 | -73.42 | -114.38 |
Free Cash Flow Free Cash Flow Growth | 32.51 | 16.05 | -0.13 | -101.3 | 15.76 | -95.41 |
Free Cash Flow Growth | -25.06% | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 46.60% | 46.62% | 45.84% | 44.36% | 54.02% | 40.06% |
Operating Margin | -12.12% | -10.75% | -10.63% | -14.84% | -15.43% | -9.83% |
Pretax Margin | -9.08% | -12.03% | -17.16% | -16.35% | -13.86% | -7.39% |
Profit Margin | -8.33% | -10.78% | -15.34% | -16.07% | -14.92% | -9.20% |
FCF Margin | 6.31% | 3.12% | -0.02% | -17.49% | 2.60% | -12.95% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
P/FCF Ratio | 58.20 | 96.28 | - | - | 106.52 | - |
PS Ratio | 3.67 | 3.01 | 2.53 | 2.82 | 2.77 | 2.25 |